RUXOLITINIB

Brand name:

• Jakavi®

Pharmaceutical company:

Novartis Pharmaceuticals Australia Pty Limited

Condition/indication:
(therapeutic use)

• Graft versus host disease

PBAC Submission type:

Change to PBS listing (–)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – September 2022

Related medicines:

• RUXOLITINIB

Submission received for:

September 2022 PBAC meeting

Opportunity for consumer comment:

Open 30/03/2022 and close 25/05/2022 (see PBS Website)

PBAC meeting:

Held on 02/09/2022

PBAC outcome published:

Not Recommended (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---